Abstract:Objective:To analyze the genetic mutations and clinical features of the subtypes of classical BCR-ABL-negative myeloproliferative neoplasm (MPN) .Methods:Mutations of 108 newly diagnosed BCR-ABL-negative MPN patients [including 55 patients with essential thrombocytopenia (ET) , 24 with polycythemia vera (PV) , and 29 with primary myelofibrosis (PMF) ] were identified using next-generation sequencing with 127-gene panel, and the relationship between gene mutations and clinical features were analyzed.Results:Total 211 mutations in 32 genes were detected in 100 MPN patients (92.59% ) , per capita carried (1.96±1.32) mutations. 85.19% (92/108) patients carried the driver gene (JAK2, CALR, MPL) mutations, 69.56% (64/92) of these patients carried at least 1 additional gene mutation. In descending order of mutation frequency, the highest frequency was for activation signaling pathway genes (42.2% , 89/211) , methylation genes (17.6% , 36/211) , and chromatin-modified genes (16.1% , 34/211) . There was a significant difference in the number of mutations in the activation signaling pathway genes, epigenetic regulatory genes, spliceosomes, and RNA metabolism genes among the three MPN subgroups. The average number of additional mutations in PMF patients was higher than that in ET and PV patients (1.69±1.39, 0.67±0.70, 0.87±1.22, χ2=13.445, P=0.001) . MPN-SAF-TSS (MPN 10 score) ( P=0.006) and myelofibrosis level ( P=0.015) in patients with ≥ 3 mutant genes were higher and the HGB level ( P=0.002) was lower than in those with<3 mutations. Twenty-six patients (24.1% ) carried high-risk mutation (HMR) , and patients with HMR had lower PLT ( P=0.017) , HGB levels ( P<0.001) , and higher myelofibrosis level ( P=0.010) and MPN10 score ( P<0.001) . The frequency of ASXL1 mutations was higher in PMF than in PV patients (34.5% vs. 4.2% , P=0.005) . PMF patients with ASXL1 had lower levels of PLT and HGB ( P=0.029 and 0.019) . Conclusion:69.56% of MPN patients carry at least one additional mutation, and 24.1% patients had HMR. Each subgroup had different mutation patterns. PMF patients had a higher average number of additional gene mutations, especially a higher frequency of ASXL1 mutation; PLT and HGB levels were lower in ASXL1 mutation PMF patients.

Genomic alterations in blast phase of BCR::ABL1-negative myeloproliferative neoplasms

A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1‐negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia‐related

Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN

Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase

Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs)

Advances in molecular evaluation of myeloproliferative neoplasms

Cytogenetics and genomics in CML and other myeloproliferative neoplasms

Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase

Genetic landscape of chronic myeloid leukemia

Characterization of Disease-Propagating Stem Cells Responsible for Myeloproliferative Neoplasm–blast Phase

Gene Mutations and the Phenotype of BCR/ABL-negative Myeloproliferative Neoplasms

MPN Transformation Is Characterized By Heterogeneous Shifts In Lineage Character Resulting In Both HSC-Like And More Differentiated Lineage Signatures

Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms

Co-occurrence of JAK2-V617 F mutation and BCR::ABL1 translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination

Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN

Analysis of Gene Mutations and Clinic Features in 108 Patients with Myeloproliferative Neoplasm

Oncogenes in myeloproliferative disorders

Advanced Forms of MPNs Are Accompanied by Chromosomal Abnormalities That Lead to Dysregulation of TP53.

Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease

Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia

Calr Vs. JAK2 Vs. MPL Mutations in the Progression of Philadelphia-Negative Myeloproliferative Neoplasms